

1. Record Nr.	UNINA9911019165603321
Titolo	Apoptosis and autoimmunity // edited by M. Hermann and J.R. Kalden
Pubbl/distr/stampa	Weinheim, : Wiley-VCH, c2003
ISBN	9786610520381 9781280520389 1280520388 9783527605293 3527605290 9783527601455 3527601457
Descrizione fisica	1 online resource (405 p.)
Altri autori (Persone)	HerrmannM, Dr. (Martin) KaldenJ. R (Joachim Robert)
Disciplina	571.9/73
Soggetti	Apoptosis Autoimmunity Autoimmune diseases
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	"From mechanism to treatments"--Cover.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Apoptosis and Autoimmunity; Preface; Contents; List of Contributors; Part 1 General Features of Apoptosis; 1 Apoptosis and Autoimmunity; 1.1 Introduction; 1.2 Autoimmune Diseases Associated with Targeted Cell Destruction; 1.2.1 What is the Mode of Cell Death?; 1.2.2 What Cells and What Effector Pathways are Responsible for Cell Death?; 1.3 Autoimmune Diseases Associated with Enhanced Cell Growth and Survival; 1.4 Autoimmune Diseases Associated with Abnormal Processing of Dying Cells; 1.5 Conclusions; 1.6 References; 2 Caspase Knockouts: Matters of Life and Death 2.1 Death, Development and Immune Function 2.2 Apoptotic Pathways: from Nematode to Mammals; 2.3 Triggering a Killer: General Aspects of Caspase Activation; 2.4 Caspase-1 and -11: More than Mediators of Inflammatory Cytokines?; 2.5 Caspase-8 and the FAS Signaling Pathway; 2.6 Caspase-3: The Chief Executioner?; 2.7 Caspase-9:

Mitochondrial Activation and the Apoptosome; 2.8 Caspase-2: A Duality of Function; 2.9 Caspase-12: Responding to Stress; 2.10 Compensatory Caspase Activation: A Caveat to Knockout Analysis; 2.11 Caspases: More than Simple Killers; 2.12 Concluding Remarks; 2.13 References

Part 2 Clearance of Apoptotic Cells

3 Anti-inflammatory and Immunoregulatory Effects of Apoptotic Cells; 3.1 Introduction; 3.2 Anti-inflammatory Effects of Apoptotic Cells on Monocytes/Macrophages; 3.3 The Role of Anti-inflammatory Cytokines for the Inhibition of Pro-inflammatory Cytokine Production; 3.4 Monocyte/Macrophage Receptors receiving the Anti-inflammatory Signal from Apoptotic Cells; 3.5 Intracellular Signaling Events Causing the Anti-inflammatory State in Macrophages; 3.6 Apoptotic Cells Impair MHC Class II Surface Expression on Monocytes

3.7 Influence of Apoptotic Cells on DC Function in Allogeneic MLR

3.8 The Presence of Apoptotic Cells can Shift the T(h) Cell Response towards T(h)2; 3.9 Apoptotic Cells Suppress Delayed-type Hypersensitivity (DTH) In Vivo; 3.10 Necrosis and Inflammation; 3.11 Implications of the Anti-inflammatory and Immunodulatory Effects of Apoptotic Cells for Health and Disease; 3.11.1 Apoptosis and Pregnancy; 3.11.2 Apoptosis and Irradiation; 3.11.3 Apoptosis and Cancer; 3.11.4 Apoptosis and Infections; 3.11.5 Apoptosis and Blood Transfusions; 3.12 References; 4 Complement and Apoptosis; 4.1 Introduction

4.2 Programmed Cell Death (PCD)

4.3 Complement; 4.4 Complement and Apoptosis; 4.4.1 Role of Complement in the Execution Phase; 4.4.2 Complement Activation by Apoptotic Cells; 4.5 Apoptosis, Complement and Autoimmunity; 4.6 References; 5 Soluble Factors that Bind to Dying Cells Control the Outcome of Corpse Disposal: The Role of Pentraxins, Collectins and Autoantibodies; 5.1 Introduction; 5.2 Soluble Factors Involved in Apoptotic Cell Recognition and Internalization; 5.2.1 Corpse Clearance at Rest: Collectins; 5.2.2 Corpse Clearance at Rest: Cationic Factors and Other PS-binding Moieties

5.2.3 Corpse Clearance during Acute Inflammation: Pentraxins

Sommario/riassunto

This is the first comprehensive book about the relationship between apoptosis and autoimmune diseases. It offers a unique up-to-date overview on research results on the defective execution of apoptosis and the incomplete clearance of apoptotic cells. The molecular and cellular mechanisms involved are described in detail. As a possible consequence of apoptotic dysfunction, the development of severe autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) is discussed. An outlook on future research topics includes the evaluation of novel therapeutic strategies.
